Y.-H. T. Lin

This study shows that human APOBEC3B causes tumor heterogeneity and metastases in mice, with increased C-to-T mutations and structural variations.

This study defines the myeloma cell surface proteome, identifies therapeutic targets and resistance biomarkers, and presents a miniaturized surface proteomics protocol.

This study identifies a secretory autophagy pathway that releases autophagy cargo receptors via extracellular vesicles when endolysosomal function is inhibited or autophagosome maturation is disrupted.

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.

The paper identifies OMA1, DELE1, and HRI as a pathway that relays mitochondrial dysfunction to the integrated stress response, showing its role in activating eIF2 kinase activity and potential therapeutic relevance.

The paper uses phosphoproteomics and transcriptomics to analyze RAS signaling in multiple myeloma, identifying distinct signaling patterns and clinical outcomes associated with NRAS and KRAS mutations.

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.